Brought to you by 
TetraPhase raises $10mm of potential $30mm second round
20 Apr 2021
Executive Summary
Three-year-old antibiotics developer TetraPhase Pharmaceuticals raised $10mm of a potential $30mm Series B equity round to nine investors including returning shareholders Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures, and Skyline Ventures. The company closed its $25mm Series A in August 2008.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TetraPhase raises $10mm of potential $30mm second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice